El ruboxistaurin, una alternativa en el edema macular diabético

摘要

Backgrounds: the macular edema is the main cause of low vision in persons with diabetic retinopathy. Objective: to analyze the results of treatment with ruboxistaurin in cases of diabetic macular edema. Development: the hyperglycemia among other metabolic alterations, to active the kinase C protein contributing to microvascular dysfunction, an important disorder in the pathogenesis of the diabetic macular edema. Different therapeutical procedures have been used in its treatment. In past years the ruboxistaurin has showed its ability to inhibit the activation of C kinase protein. Some authors consider that this drug is able to improve the diabetic macular edema and thus, the vision. It has been reported that the administration of 32 mg daily de ruboxistaurin prevents the progression of the diabetic retinopathy and decrease the risk of visual loss from diabetic macular edema. Other studies describe similar results and also, report that this drug decreases the risk or worsening and progression of this type of edema as well as to reduce the need of laser treatment. Conclusions: the use of ruboxistaurin open new perspectives for prevention and treatment of visual deficit due to diabetic retinopathy and from the diabetic macular edema, however, authors consider that the studies conducted until now are insufficient to arrive to valid conclusions. Studies at longer term are necessary to define its cost/benefit.